---
title: "Weekly Recap: India approves QDENGA and LATITUDE PsO trial success"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293259116.md"
description: "Takeda received Indian approval for its dengue vaccine QDENGA, enabling use without prior testing, and is scaling production with Biological E to 50 million doses annually. Additionally, Takeda reported positive Phase 3 LATITUDE trial results for psoriasis, showing ~70% skin clearance by week 16 with durable safety through week 24."
datetime: "2026-07-20T22:14:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293259116.md)
  - [en](https://longbridge.com/en/news/293259116.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293259116.md)
generator: "portal-rs"
---

# Weekly Recap: India approves QDENGA and LATITUDE PsO trial success

Takeda (TSE:4502) won India approval for its tetravalent dengue vaccine QDENGA for use without prior testing and is scaling supply with Biological E toward 50M doses yearly, while its Phase 3 LATITUDE PsO trials showed ~70% skin clearance and durable, consistent safety through week 24.

**Previous Week Recap**

-   **Takeda Dengue Vaccine Approved**: Takeda (4502) says India approved its tetravalent dengue vaccine QDENGA, usable without prior testing. Takeda partners with Biological E to scale production toward 50 million doses annually. 1
-   **Latitude PsO Late-Stage Results**: Takeda’s Phase 3 LATITUDE PsO trials: ~70% reached sPGA 0/1 and PASI 75 by week 16 vs placebo; high clearance at scalp, nails, palms/soles; responses durable to week 24; safety consistent. 2

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO](https://longbridge.com/en/news/297377145.md)
- [Weekly Recap: MIMRYLO license terms and Orzeyful FDA approval](https://longbridge.com/en/news/297567010.md)
- [Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1](https://longbridge.com/en/news/296890461.md)
- [Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug](https://longbridge.com/en/news/297545595.md)
- [Takeda adds boxed warning on ADZYNMA over risk of neutralizing antibodies to ADAMTS13](https://longbridge.com/en/news/296794493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**